HOME >> MEDICINE >> NEWS
New data supports a non-invasive approach to routine prenatal genetic testing

. Kenneth Moise, Professor of Obstetrics and Gynecology and a specialist in Maternal-Fetal Medicine at Baylor College of Medicine in Houston, Texas, this is a major research breakthrough in prenatal medicine.

"This is potentially one of the biggest steps forward to determine genetic conditions in the fetus. The ability to make an early diagnosis is the key that opens the door for the future treatment of many birth defects before the child is born," says Dr. Moise. "This shows promise as an excellent alternative to amniocentesis and may give expectant parents peace of mind."

Through technology licensing agreements with clinical laboratories, Sequenom expects a non-invasive application of its technology for fetal Rhesus D (RhD) typing to become available in these laboratories beginning in the first half of 2007. Rhesus disease can occur when the blood of the expectant mother is incompatible with her unborn child. According to the Centers for Disease Control and Prevention (CDC), the incidence of hemolytic disease caused by RhD incompatibility in newborns occurs in approximately 1 in 1,000 live born infants. Complications from RhD disease can lead to jaundice, anemia, brain damage, heart failure, and death.

"We are making significant progress in developing our proprietary Fetal Nucleic Acid Technology and anticipate applying our novel approach to multiple prenatal tests such as tests for RhD, cystic fibrosis, Down syndrome, and others," said Dr. Harry Stylli, Sequenom President and Chief Executive Officer. "We believe our technology has great potential to substantially improve the standard of care for all pregnant mothers."


'"/>

Contact: David Schemelia
dschemelia@healthstarpr.com
646-722-8819
HealthStar PR
9-Feb-2007


Page: 1 2

Related medicine news :

1. Michigan-CDC study supports value of social restrictions during influenza pandemics
2. ACP supports improved access to information on relative strengths and weaknesses
3. Study supports activity of GEMZAR in the treatment of early-stage breast cancer
4. New research supports early testing for prostate cancer
5. ACP enthusiastically supports introduction of Bipartisan Health CARE Act
6. ACP supports new bill to promote adoption of health information technology
7. Existing research supports metabolic syndrome link to cardiovascular disease
8. Medscape review supports effectiveness and safety of new non-drug blood pressure treatment
9. New study supports major change in diet treatment for diabetes
10. Wild vs. lab rodent comparison supports hygiene hypothesis
11. British public supports use of personal data for health research

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/16/2019)... , ... November 15, 2019 , ... ... living with memory impairment, has announced the Best Memory Care Facilities in Amarillo, ... experts, facility features and amenities. , According to the Alzheimer’s Association ...
(Date:11/15/2019)... ... November 15, 2019 , ... PlayCore’s Center ... comprehensive school physical activity programs (CSPAP) on December 3, 2019 at 2 p.m. ... park professionals, this one-hour and 15-minute webinar will discuss the five components of ...
(Date:11/14/2019)... (PRWEB) , ... November 14, 2019 , ... ... cardiologists at Loma Linda University International Heart Institute have performed a ... single access from the axillary artery in the shoulder. The new procedure offers ...
(Date:11/14/2019)... , ... November 14, 2019 , ... ... Drug Administration (FDA) has granted acceptance to file status of its application for ... manifestation in the disease neurofibromatosis type one (NF1). The FDA’s acceptance of the ...
(Date:11/12/2019)... ... November 12, 2019 , ... InteliChart, the ... that Tidewater Physicians Multispecialty Group (TPMG), a network of 220 providers ... patient engagement platform to deliver enhanced patient experience and overall engagement to ...
Breaking Medicine News(10 mins):
(Date:11/14/2019)... ... November 14, 2019 , ... Bioclinica Medical ... that it has reached a milestone in the company’s history: the company has ... submissions from biopharmaceutical clients for therapies and indications subsequently approved by the U.S. ...
(Date:11/14/2019)... NEW YORK (PRWEB) , ... November 14, 2019 ... ... national brand, K-FISH, aimed to promote the quality of Korean seafood and enhance ... two-week-long promotions entitled, "K-Seafood Global Weeks" in many countries. These special events ...
(Date:11/11/2019)... Fla. (PRWEB) , ... November 11, 2019 , ... ... excellence for autologous biologics, is now representing two of the most respected manufacturers in ... Based in Germany, Ameia Med is the leading developer of the ...
Breaking Medicine Technology:
Cached News: